A Phase I Dose Escalation Study of Eryaspase in Combination With Modified FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma

This will be a single-arm, multi-center, open-label phase 1 study. The standard 3+3 design will be used to determine the maximum tolerated dose (MTD) from 4 possible dose levels of Eryaspase in combination with mFOLFIRINOX. We hypothesize that the addition of Eryaspase to FOLFIRINOX (5-fluorouracil [5-FU], leucovorin, irinotecan, and oxaliplatin) will be safe and demonstrate preliminary signs of efficacy in patients with advanced pancreatic cancer. Safety assessments include adverse events, physical examination abnormalities, vital signs, and clinical laboratory tests (including blood chemistry, hematology, and coagulation panel).

Start Date02 Dec 2020

Sponsor / Collaborator

Georgetown University

[+1]

EUCTR2018-000572-15-AT

/ Not yet recruitingPhase 3

A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma - TRYbeCA-1– TRial of erYaspase in pancreatic CAncer

Start Date08 Oct 2018

Sponsor / Collaborator

ERYTech Pharma SA

NCT03665441

/ CompletedPhase 3

A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma

This is an open-label, multicenter, randomized, Phase 3 study in patients with ductal adenocarcinoma of the pancreas who have failed only one prior line of systemic anti-cancer therapy for advanced pancreatic cancer and have measurable disease.

Start Date15 Sep 2018

Sponsor / Collaborator

ERYTech Pharma SA

100 Clinical Results associated with Asparaginase erythrocyte encapsulated(ERYTech Pharma SA)

100 Translational Medicine associated with Asparaginase erythrocyte encapsulated(ERYTech Pharma SA)

100 Patents (Medical) associated with Asparaginase erythrocyte encapsulated(ERYTech Pharma SA)

Literatures (Medical) associated with Asparaginase erythrocyte encapsulated(ERYTech Pharma SA)

01 Feb 2023·Cancer Treatment Reviews

Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review

Review

Author: Wainberg, Zev A ; Johnson, Andrew ; Dayyani, Farshid ; Macarulla, Teresa

INTRODUCTIONThe aim of this review was to characterize the second- and later-line (≥2L) treatment landscape for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).METHODSThis systematic literature review (PROSPERO: CRD42021279753) involved searches of MEDLINE® and Embase to identify results from prospective studies of ≥2L treatment options for metastatic pancreatic cancer published from 2016 to 2021. Publications were screened according to predetermined eligibility criteria; population-level data were extracted using standardized data fields. Publication quality was assessed according to Grading of Recommendations Assessment, Development and Evaluation (GRADE). The data were analyzed descriptively, grouped by drug class.RESULTSSixty publications were identified, including 23 relating to comparative trials. GRADE assessment found that, of these 23 trials, 83% reported high or moderate-quality evidence. Of the publications relating to comparative trials, nine (three trials) reported favorable results: the pivotal phase 3 NAPOLI-1 trial for liposomal irinotecan; a phase 3 trial of non-liposomal irinotecan within the FOLFIRINOX regimen; and a phase 2 trial of eryaspase plus chemotherapy.CONCLUSIONSThe level of unmet need for ≥2L treatment options for mPDAC remains high. Irinotecan-based regimens currently offer the greatest promise. Investigations into paradigm-changing agents and combination approaches continue.

01 Sep 2022·British Journal of Haematology

Is asparaginase encapsulated in erythrocytes effective as second‐line treatment in acute lymphoblastic leukaemia?

Letter

Author: Pieters, Rob ; Bertrand, Yves ; van der Sluis, Inge M. ; Baruchel, André

With interest, we have read the recent article by Lynggaard and colleagues.They studied a new formulation of asparaginase encapsulated in erythrocytes (Eryaspase) in acute lymphoblastic leukemia (ALL) patients with a prior hypersensitivity reaction to pegylated E. coli asparaginase.Eryaspase was well-tolerated and most patients had therapeutic asparaginase levels after the first infusion.

01 Jun 2022·British Journal of HaematologyQ2 · MEDICINE

Asparaginase encapsulated in erythrocytes as second‐line treatment in hypersensitive patients with acute lymphoblastic leukaemia

Q2 · MEDICINE

Article

Author: Albertsen, Birgitte Klug ; El Hariry, Iman ; Lehmann, Anne Kristine ; Schmiegelow, Kjeld ; Vaitkeviciene, Goda ; Lepik, Kristi ; Lynggaard, Line Stensig ; Lähteenmäki, Päivi M. ; Langenskiöld, Cecilia

SummaryAsparaginase is essential in treating acute lymphoblastic leukaemia (ALL). Asparaginase‐related hypersensitivity causes treatment discontinuation, which is associated with decreased event‐free survival. To continue asparaginase treatment after hypersensitivity, a formulation of asparaginase encapsulated in erythrocytes (eryaspase) was developed. In NOR‐GRASPALL 2016 (NCT03267030) the safety and efficacy of eryaspase was evaluated in 55 patients (aged 1–45 years; median: 6.1 years) with non‐high‐risk ALL and hypersensitivity to asparaginase conjugated with polyethylene glycol (PEG‐asparaginase). Eryaspase (150 u/kg) was scheduled to complete the intended course of asparaginase (1–7 doses) in two Nordic/Baltic treatment protocols. Forty‐nine (96.1%) patients had asparaginase enzyme activity (AEA) ≥100 iu/l 14 ± 2 days after the first eryaspase infusion [median AEA 511 iu/l; interquartile range (IQR), 291–780], whereas six of nine (66.7%) patients had AEA ≥100 iu/l 14 ± 2 days after the fourth infusion (median AEA 932 iu/l; IQR, 496–163). The mean terminal half‐life of eryaspase following the first infusion was 15.3 ± 15.5 days. Few asparaginase‐related adverse events were reported; five patients (9.1%) developed clinical allergy associated with enzyme inactivation. Replacement therapy was successfully completed in 50 patients (90.9%). Eryaspase was well tolerated, and most patients had AEA levels above the therapeutic target after the first infusion. The half‐life of eryaspase confirmed that a 2‐week schedule is appropriate.

News (Medical) associated with Asparaginase erythrocyte encapsulated(ERYTech Pharma SA)

26 Jun 2023

·www.fiercebiotech.com

Erytech's merger with Pherecydes reaches the finish line after contentious few months

Erytech and Pherecydes will merge to become Phaxiam Therapeutics. Erytech shareholders have sided with the company over a persistent activist investor, greenlighting a merger with Pherecydes months after the proposed deal was first announced. The French biotech said shareholders approved all resolutions that the board was in favor of at a shareholder meeting Friday, the most important of which was a merger with Pherecydes. The joint venture will be called Phaxiam Therapeutics. The wave-through from Erytech’s shareholders marks the end of a contentious few months that pitted the company against activist shareholder Akkadian Partners, which owns roughly 5% of the company’s stock. Akkadian said in May that it thought the proposed value of Pherecydes was “unjustified” following a top-down review of the proposed merger. The investors concluded that the deal did not serve the best interests of Erytech’s shareholders. Erytech has been unwavering in its counter-campaign, calling the statements from Akkadian “disinformation” and saying that the company’s best hope for survival was the merger. Whatever potential Akkadian believed Erytech had without the merger was misguided, the company contended. Erytech has been in a state of flux since the end of 2021 after pivoting the indication of lead asset eryaspase to leukemia following a late-stage flop in patients with pancreatic cancer. Less than a year later, the company dropped the asset all together to focus energy and resources on its drug delivery platform. Merging with Pherecydes will be a reentry into the drug development space—albeit a totally different genre. Pherecydes is developing a series of bacteriophages meant to tackle bacterial infections and antimicrobial resistance. One of the company’s top priorities is a phase 2 phage therapy to treat prosthetic joint infection due to Staphylococcus aureus. The first patient was enrolled a year ago, but there’s been no update to the clinical trial record since, with enrollment still ongoing, according to the record.

Phase 2

23 Jun 2023

·www.globenewswire.com

ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023

ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023 All resolutions voted with a large majority according to Board of Directors recommendationsCompany renamed Phaxiam Therapeutics, creating a world leader in phage therapy Lyon (France), June 23, 2023 – ERYTECH Pharma (Euronext Paris & Nasdaq: ERYP) announced today that all resolutions for which the Board of Directors recommended a vote in favor, including the approval of the merger with Pherecydes, were adopted by its shareholders at the Combined General Meeting that was held today, June 23, 2023 The adopted resolutions include: Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2022;Allocation of the financial year's results;Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2022 to Gil BEYEN and Jean-Paul KRESS and of the compensation policy for executive corporate officers and board members;Renewal of the terms of office as Directors of Hilde WINDELS BV and Mrs. Martine George;Ratification of the appointment of Mr. Didier Hoch and Go Capital (Mrs. Leila Nicolas) as Directors;Appointment of Mr. Robert Sebbag and Mr. Eric Leire as Directors;Approval of the merger with Pherecydes and modification of the corporate name;Delegation of authority to the Board of Directors to carry out a reverse stock-split;Delegations of authority to the Board of Directors to issue shares or other marketable securities convertible into shares to be issued immediately or in the future by the Company, with or without preferential subscription rights for the shareholders;Authorization for the Board of Directors to grant free shares, share subscription and/or share purchase options and/or to issue share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma Group. The full results of all matters voted on at the meeting can be viewed on the Company’s website at www.erytech.com, within the Shareholders Meeting/2023 section under the Investors tab. The merger between Erytech and Pherecydes has been approved by the Combined General Meeting on the basis of an exchange ratio of 4 Pherecydes shares for 15 Erytech shares (the "Merger") which gave full powers to Erytech's Board of Directors to record the definitive completion of the Merger. Erytech shareholders also approved the change of Erytech's corporate name to "Phaxiam Therapeutics". At the Pherecydes Combined General Meeting held today at 1pm, after the Erytech Combined General Meeting, all the resolutions supported by the Pherecydes Board of Directors were approved, including those relating to the Merger. The Erytech Board of Directors met after the Pherecydes Combined General Meeting and acknowledged the completion of the Merger. The Merger took effect today and entails the dissolution of Pherecydes without liquidation. For accounting and tax purposes, the Merger is retroactive to January 1st, 2023. These approvals will enable the creation of Phaxiam Therapeutics, a world leader in phage therapy, to meet the major challenges of public health and European sovereignty. The new Phaxiam Therapeutics shares resulting from the Merger will be admitted to trading on compartment C of Euronext Paris under ISIN code FR0011471135 on June 29, 2023. Settlement and delivery of the new Phaxiam Therapeutics shares will take place on July 3, 2023. In the event that the number of Phaxiam Therapeutics shares to which a Pherecydes shareholder is entitled does not correspond to a whole number of Phaxiam Therapeutics shares, the shareholder will receive the number of shares immediately below, plus the balance in full, a balancing payment in cash based on the price at which the Phaxiam Therapeutics shares corresponding to fractional shares have been sold by the financial intermediaries, within thirty days of the latest of the dates on which the number of Phaxiam Therapeutics shares allotted is recorded in the account of Pherecydes shareholders. Indicative timetable of the Merger process following the Combined Shareholder's Meeting: Erytech's Board of Directors acknowledging the definitive completion of the Merger and deciding on the corresponding capital increase.June 23, 2023Publication of Euronext notice relating to the issue of new shares in consideration for the Merger.June 26, 2023Settlement and admission to trading on the regulated market of Euronext Paris of the new shares issued in consideration for the Merger.July 3, 2023Registration with the SEC and listing on Nasdaq of the American Depositary Shares (ADS) representing the new shares issued as consideration for the Merger.July 3, 2024 About ERYTECH ERYTECH is a biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. On February 15, 2023, ERYTECH announced its intended strategic combination with PHERECYDES to create a global player in extended phage. More detail can be found in the press release. ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit www.erytech.com CONTACTS ERYTECH Eric SoyerCFO & COONewCapMathilde Bohin / Louis-Victor DelouvrierInvestor relationsNicolas MerigeauMedia relations+33 4 78 74 44 38investors@erytech.com+33 1 44 71 94 94 erytech@newcap.eu Forward-looking information This press release contains forward-looking statements, forecasts and estimates with respect to the clinical results from and the development plans of eryaspase, business and regulatory strategy and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding ERYTECH’s business and regulatory strategy and its evaluation of potential strategic transactions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (1) the failure to achieve certain regulatory and commercial milestones; (2) the inability to maintain the listing of ERYTECH’s shares on the Nasdaq Global Select market and the Euronext regulated market; (3) changes in applicable laws or regulations; (4) the possibility that ERYTECH may be adversely affected by other economic, business and/or competitive factors; (5) the inability to agree to terms on a long-term supply agreement with Catalent; and (6) other risks and uncertainties indicated from time to time in ERYTECH’s regulatory filings. Further description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company’s Securities and Exchange Commission (SEC) filings and reports, including in the Company’s 2021 Universal Registration Document (Document d’Enregistrement Universel) filed with the AMF on April 27, 2022 and in the Company’s Annual Report on Form 20-F filed with the SEC on April 28, 2022 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law. Attachment ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023

Executive Change

20 Jun 2023

·www.globenewswire.com

ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit

ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit Cambridge, MA (U.S.) and Lyon (France), June 20, 2023 – ERYTECH Pharma (Euronext Paris and Nasdaq: ERYP) announces the filing of a new lawsuit by Akkadian Partners. Despite the rejection by the President of the Lyon Commercial Court of Akkadian Partners' request to postpone the General Meeting's vote on the proposed merger, Akkadian has initiated new legal proceedings with the clear aim of continuing its attempt to destabilize Erytech. As part of this new procedure, the first hearing of which will take place after the vote on the merger, Akkadian Partners is requesting the cancellation of the capital increase of May 15, 2023. This capital increase, resulting from contributions in kind of Pherecydes shares in exchange for ERYTECH shares, had been announced at the time of the merger announcement last February and had been carried out in accordance with the delegation of authority granted by the 2022 extraordinary general meeting of ERYTECH shareholders under resolution 29 and on the basis of reports issued by Finexsi, acting as a contribution appraiser (commissaire aux apports), in accordance with Articles L. 225-147, R. 22-10-7 and R. 225-136 of the French Commercial Code as well as AMF recommendation no. 2020-06. Erytech is confident of the outcome of this unfounded procedure, which appears bound to failure. About ERYTECH ERYTECH is a biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. On February 15, 2023, ERYTECH announced its intended strategic combination with PHERECYDES to create a global player in extended phage. More detail can be found in the press release. ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit www.erytech.com CONTACTS ERYTECH Eric SoyerCFO & COONewCapMathilde Bohin / Louis-Victor DelouvrierInvestor relationsNicolas MerigeauMedia relations+33 4 78 74 44 38investors@erytech.com+33 1 44 71 94 94 erytech@newcap.eu Forward-looking information This press release contains forward-looking statements, forecasts and estimates with respect to the clinical results from and the development plans of eryaspase, business and regulatory strategy and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding ERYTECH’s business and regulatory strategy and its evaluation of potential strategic transactions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (1) the failure to achieve certain regulatory and commercial milestones; (2) the inability to maintain the listing of ERYTECH’s shares on the Nasdaq Global Select market and the Euronext regulated market; (3) changes in applicable laws or regulations; (4) the possibility that ERYTECH may be adversely affected by other economic, business and/or competitive factors; (5) the inability to agree to terms on a long-term supply agreement with Catalent; and (6) other risks and uncertainties indicated from time to time in ERYTECH’s regulatory filings. Further description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company’s Securities and Exchange Commission (SEC) filings and reports, including in the Company’s 2021 Universal Registration Document (Document d’Enregistrement Universel) filed with the AMF on April 27, 2022 and in the Company’s Annual Report on Form 20-F filed with the SEC on April 28, 2022 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law. Attachment PR_ERYTECH_200623_EN_VF

Acquisition

100 Deals associated with Asparaginase erythrocyte encapsulated(ERYTech Pharma SA)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Lymphoblastic Leukemia	Phase 3	European Union	ERYTech Pharma SA	-
Pancreatic adenocarcinoma	Phase 2	France	ERYTech Pharma SA	15 Sep 2018
Pancreatic adenocarcinoma	Phase 2	United Kingdom	ERYTech Pharma SA	15 Sep 2018
Pancreatic adenocarcinoma	Phase 2	United States	ERYTech Pharma SA	15 Sep 2018
Acute Myeloid Leukemia	Phase 2	France	ERYTech Pharma SA	01 Feb 2013
Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia	Phase 2	Belgium	ERYTech Pharma SA	01 Dec 2009
Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia	Phase 2	France	ERYTech Pharma SA	01 Dec 2009
Recurrent Adult Acute Lymphoblastic Leukemia	Phase 2	France	ERYTech Pharma SA	01 Dec 2009
Recurrent Adult Acute Lymphoblastic Leukemia	Phase 2	Belgium	ERYTech Pharma SA	01 Dec 2009
Acute Lymphoblastic Leukemia	Phase 2	European Union	ERYTech Pharma SA	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04292743 (CTgov)	Phase 1	Advanced Pancreatic Ductal Adenocarcinoma \| Metastatic Pancreatic Ductal Adenocarcinoma	19	Leucovorin Calcium+Eryaspase+irinotecan+oxaliplatin+Irinotecan hydrochloride+FLUOROURACIL (Eryaspase Dose Level 0 (75 Units/kg) Plus FOLFIRINOX)	wbentvtzpy(umkivxncpl) = cinmxtmdni gyhsmaoafm (gvcdmtcgxx, puvavzjpln - tnndnkptip) View more	-	14 Feb 2025
NCT04292743 (CTgov)	Phase 1		19	FOLFIRINOX+Eryaspase (Eryaspase Dose Level 1 (100 Units/kg) Plus FOLFIRINOX)	wbentvtzpy(umkivxncpl) = yaoebnnuvj gyhsmaoafm (gvcdmtcgxx, kazyrxvdlf - eelkbxpbky) View more	-	14 Feb 2025
NCT03267030 (CTgov)	Phase 2	Acute Lymphoblastic Leukemia \| Hypersensitivity	55	GRASPA	ujppivzuwd(hyimetufhy) = upwhraedth rutrsjjxpb (fftzxxasgh, qmrazeewvk - qaagtvuasq) View more	-	15 Mar 2024
NCT04292743 (ASCO 12023 \| ASCO 22023) Manual	Phase 1	Pancreatic Ductal Adenocarcinoma	18	mFOLFIRINOX+Eryaspase	(bchgbdzbbf) = hypokalemia (22%), fatigue (11%), anemia (6%), hypotension (6%), diarrhea (6%), syncope (6%), and atrial fibrillation (6%). obwxojvhbr (wkxmaxodaq )	Positive	31 May 2023
NCT03665441 (Trybeca-1, CTgov)	Phase 3	Pancreatic adenocarcinoma	512	Abraxane+eryaspase+leucovorin+Gemcitabine+Irinotecan+5-FU (Eryaspase Plus Chemotherapy)	(zlljvximyi) = htfbmnmblh nuebbuxmqq (rfokkhjvdz, fanpohqlwd - cqzdkdextb) View more	-	28 Sep 2022
NCT03665441 (Trybeca-1, CTgov)	Phase 3	Pancreatic adenocarcinoma	512	Abraxane+leucovorin+Gemcitabine+Irinotecan+5-FU (Chemotherapy Alone)	(zlljvximyi) = bqwrwskyms nuebbuxmqq (rfokkhjvdz, lrlulvibyo - eyyovnmbdv) View more	-	28 Sep 2022
NCT03267030 (Pubmed \| Int J Radiat Oncol Biol Phys) Manual	Phase 2	Pre B-cell acute lymphoblastic leukemia Second line	55	eryaspase	(kaoejuclii) = equvsakojq bwveovqjru (kewarqkceq, 15.5) View more	Positive	01 Jun 2022
NCT00723346 (Corporate Publications) Manual	Phase 2	Acute Lymphoblastic Leukemia	-	GRASPA	hrufsdawjy(xcbvjvspbj) = glhzknrhrs kuazexiaok (yapojjbvpp ) View more	Positive	06 Apr 2022
NCT01810705 (ENFORCE, CTgov)	Phase 2	Acute Myeloid Leukemia	123	GRASPA (GRASPA)	(bjnhsiyyrj) = feyibekkae sbjqntmyit (wrxrownblj, qbfkglpijr - pnyezwdhti) View more	-	21 Feb 2022
NCT01810705 (ENFORCE, CTgov)	Phase 2	Acute Myeloid Leukemia	123	cytarabine (Control)	(bjnhsiyyrj) = nrhpryvzfc sbjqntmyit (wrxrownblj, ljziivzari - zrzlwvmfef) View more	-	21 Feb 2022
NCT01518517 (GRASPIVOTALL, CTgov)	Phase 2/3	Acute lymphoblastic leukemia recurrent \| Recurrent Adult Acute Lymphoblastic Leukemia \| Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia	85	L-asparaginase	nrgowaqvee(mshzulwuip) = asuqbbdbqv sdepckwzyv (ehtznmqetr, qhdbqzlghh - nwouvjwmux)	-	02 Feb 2022
NCT03665441 (Trybeca-1, ASCO_GI2022) Manual	Phase 3	Advanced Pancreatic Adenocarcinoma Second line	512	chemotherapy+eryaspase	(eelgkwcjmj) = vjcmwlzuwr dtvdfatrlh (vsrinogvfy, 6.5 - 8.3) View more	Positive	19 Jan 2022
NCT03665441 (Trybeca-1, ASCO_GI2022) Manual	Phase 3	Advanced Pancreatic Adenocarcinoma Second line	512	chemotherapy	(eelgkwcjmj) = jcgzmxzgap dtvdfatrlh (vsrinogvfy, 5.4 - 7.5) View more	Positive	19 Jan 2022
NCT04292743 (ASCO_GI2022) Manual	Phase 1	Metastatic Pancreatic Ductal Adenocarcinoma	9	eryaspase+FOLFIRINOX	(dsazernzix) = The MTD has been declared with 5-FU 2400 mg/2, Oxaliplatin 85 mg/2, Irinotecan 150 mg/m2, and Eryaspase 100 units/kg. mocgofoxhi (apkjyrlziu ) View more	Positive	19 Jan 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Asparaginase erythrocyte encapsulated(ERYTech Pharma SA)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation